Mannkind Corp MNKD
We take great care to ensure that the data presented and summarized in this overview for MANNKIND CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MNKD
View all-
Black Rock Inc. New York, NY22.6MShares$121 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$97.7 Million0.0% of portfolio
-
State Street Corp Boston, MA10.7MShares$57.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA7.62MShares$41 Million0.0% of portfolio
-
Nitorum Capital, L.P. New York, NY7.01MShares$37.7 Million4.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.85MShares$31.5 Million0.4% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.48MShares$24.1 Million0.01% of portfolio
-
Qube Research & Technologies LTD London, X04.07MShares$21.9 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.05MShares$21.8 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny3.39MShares$18.2 Million0.03% of portfolio
Latest Institutional Activity in MNKD
Top Purchases
Top Sells
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Insider Transactions at MNKD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 05
2025
|
Stuart A Tross Chief People & Workpl Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,755
+1.17%
|
$38,265
$3.92 P/Share
|
|
Jul 16
2025
|
Steven B. Binder |
SELL
Open market or private sale
|
Direct |
75,367
-8.32%
|
$226,101
$3.94 P/Share
|
|
Jul 16
2025
|
David Thomson EVP Genl Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
7,466
-0.88%
|
$22,398
$3.94 P/Share
|
|
Jul 15
2025
|
Steven B. Binder |
SELL
Payment of exercise price or tax liability
|
Direct |
19,383
-2.09%
|
$58,149
$3.85 P/Share
|
|
Jul 15
2025
|
Christopher B Prentiss Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,540
-3.25%
|
$34,620
$3.85 P/Share
|
|
Jul 15
2025
|
Lauren M Sabella EVP Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
11,896
-3.29%
|
$35,688
$3.85 P/Share
|
|
Jul 15
2025
|
David Thomson EVP Genl Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
30,361
-3.45%
|
$91,083
$3.85 P/Share
|
|
Jul 15
2025
|
Stuart A Tross Chief People & Workpl Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,057
-2.56%
|
$84,171
$3.85 P/Share
|
|
Jul 15
2025
|
Michael Castagna Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
111,275
-4.25%
|
$333,825
$3.85 P/Share
|
|
Jul 15
2025
|
Sanjay R Singh EVP Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
15,450
-3.05%
|
$46,350
$3.85 P/Share
|
|
Jul 15
2025
|
Burkhard Blank EVP Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,556
-2.03%
|
$28,668
$3.85 P/Share
|
|
Jun 10
2025
|
Steven B. Binder |
SELL
Open market or private sale
|
Direct |
64,085
-6.48%
|
$256,340
$4.0 P/Share
|
|
May 27
2025
|
Burkhard Blank EVP Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,630
-3.25%
|
$62,520
$4.12 P/Share
|
|
May 20
2025
|
David Thomson EVP Genl Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
2,345
-0.27%
|
$9,380
$4.41 P/Share
|
|
May 20
2025
|
Steven B. Binder |
SELL
Open market or private sale
|
Direct |
12,078
-1.21%
|
$48,312
$4.4 P/Share
|
|
May 19
2025
|
David Thomson EVP Genl Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
9,536
-1.07%
|
$38,144
$4.37 P/Share
|
|
May 19
2025
|
Steven B. Binder |
SELL
Payment of exercise price or tax liability
|
Direct |
5,190
-0.52%
|
$20,760
$4.37 P/Share
|
|
May 19
2025
|
Michael Castagna Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,114
-0.99%
|
$104,456
$4.37 P/Share
|
|
May 19
2025
|
Stuart A Tross Chief People & Workpl Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,147
-0.56%
|
$24,588
$4.37 P/Share
|
|
May 14
2025
|
Dominic Marasco Pres, Endocrine Business Unit |
BUY
Grant, award, or other acquisition
|
Direct |
81,429
+11.1%
|
$162,858
$2.28 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.92M shares |
|---|---|
| Exercise of conversion of derivative security | 135K shares |
| Payment of exercise price or tax liability | 1.02M shares |
|---|---|
| Open market or private sale | 464K shares |
| Other acquisition or disposition | 39.5K shares |